FDA Grants Zymeworks' ZW191 Fast Track Designation for Platinum-Resistant Ovarian Cancer

Zymeworks' investigational drug ZW191 has been granted Fast Track designation by the FDA for platinum-resistant ovarian cancer treatment. ZW191 is an antibody-drug conjugate targeting folate receptor, overexpressed in approximately 75% of high-grade serous ovarian carcinomas. The FDA's Fast Track designation aims to expedite development and review of drugs addressing serious conditions with unmet medical needs. Shares are up over 3% at $24.73 in premarket trading.